Christopher Wood, MD
Neurology · Crestview Hills, KYNPI 1831624774
Payments from drug & device makers
What this record shows
This record is dominated by grants: $15,000 of the $16,440 with a category attached, or 91.2%. Medtronic accounts for 91.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $15,016 and has fallen 95.2% since, to $715 in 2025.
Across 76 payments — averaging $216.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Amneal Pharmaceuticals LLC$369
- Abbott$151
- Ipsen Biopharmaceuticals, Inc$148
- MDD US Operations, LLC$110
- AbbVie$103
- plus $559 from 18 others
What the payments were for
- Grants$15,00091%
- Food & beverage$1,4409%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $15,000 |
| Amneal Pharmaceuticals LLC | 33 | $369 |
| Abbott | 2 | $151 |
| Ipsen Biopharmaceuticals, Inc | 6 | $148 |
| MDD US Operations, LLC | 1 | $110 |
| AbbVie | 6 | $103 |
| Merz Pharmaceuticals, LLC | 2 | $57 |
| Pfizer | 3 | $55 |
| Jazz Pharmaceuticals Inc. | 3 | $50 |
| Lilly USA, LLC | 3 | $49 |
| Cycle Pharmaceuticals Inc | 2 | $36 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Lundbeck LLC | 1 | $31 |
| Sanofi | 1 | $30 |
| Revance Therapeutics, Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $25 |
| Argenx US, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Insmed, Inc. | 1 | $20 |
| Aucta Pharmaceuticals, Inc. | 1 | $19 |
| CSL Behring | 1 | $18 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,440 in reported general payments places this provider in the 80th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $70,927 |
| RytaryCarbidopa/Levodopa | 35 | $43,608 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 354 | $11,667 |
| RivastigmineRivastigmine Tartrate | 129 | $5,057 |
| Primidone | 167 | $2,866 |
| Entacapone | 18 | $1,859 |
| Donepezil Hcl | 81 | $1,507 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 46 | $1,231 |
| Propranolol Hcl ErPropranolol Hcl | 24 | $1,087 |
| Lacosamide | 17 | $956 |
| Clonazepam | 42 | $901 |
| Propranolol Hcl | 63 | $860 |
| Levetiracetam | 28 | $720 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 27 | $676 |
| Gabapentin | 55 | $590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $25 | $70,92715 claims |
| Amneal Pharmaceuticals LLCRytary | $369 | $43,60835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 210 neurology providers in Kentucky.
Other neurology in Crestview Hills
- Philip BeckerCrestview Hills$94K
- Maureen LiCrestview Hills$16K
- James WinkleyLexington$807K
- Nicole EvermanLexington$355K
- Toufic FakhouryLexington$278K
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Naveed AhmedPikeville$215K
- Angela HardwickLouisville$187K
- Peter HederaLouisville$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.